Clene to present at May investor conferences, advancing neurodegenerative disease treatments.

Clene Inc., a biopharmaceutical company focused on neurodegenerative diseases like ALS and MS, announced it will present at two investor conferences in May 2026. The presentations aim to update investors on its late-stage clinical progress, particularly for its investigational therapy CNM-Au8®, which targets mitochondrial health to protect neuronal function. This engagement highlights Clene's ongoing efforts to advance treatments for diseases such as ALS, Parkinson’s, and multiple sclerosis. Investors can expect further updates following these events.